Purpose of Review Lipoprotein(a) has emerged as a strong independent risk factor for cardiovascular disease. Targeted screening recommendations for Lp(a) measurement exist for adults and youth known to be at high-risk. However, Lp(a) measurements are not included in universal screening guidelines i...
Review article Lipoprotein lipase and the disposition of dietary fatty acidsFielding, Barbara AFrayn, Keith N
Several distinctive properties of Lp(a) can be attributed to the presence of apo(a). This review discusses the current state of literature on pathophysiological and clinical aspects of Lp(a). After five decades of research, the understanding of Lp(a) structure, biochemistry, and pathophysiology ...
Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk Michaela B. Rehman & Benoit V. Tudrej Lipids in Health and Disease volume 23, Article number: 316 (2024) Cite this article 202 Accesses Metrics details Abstract...
Aside from the presence of unique acute health conditions that may temporarily increase Lp(a) levels, there is little lifestyle or environmental contribution to Lp(a) serum levels. Literature Review Lp(a) was first discovered in 1963 by Kare Berg during an investigation of several lipoproteins ...
The role of lipoprotein-A [Lp (a)] as a risk factor for stroke is less well documented than for coronary heart disease. Hence, we conducted a systematic review and meta-analysis for the published observational studies in order to investigate the associat
This review suggests that chemotherapeutic agents may influence lipoprotein(a) (Lp(a)) concentrations in breast cancer survivors after CHT based on many convincing evidence from epidemiologic and observational researches. Usually, the higher the Lp(a) concentration, the higher the median risk of develo...
Review Article Published: 23 January 2019 Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular diseaseMichael B. Boffa & Marlys L. Koschinsky Nature Reviews Cardiology volume 16, pages 305–318 (2019)Cite this article ...
Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289–97. Article CAS PubMed Google Scholar Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. ...
In the current study, we excluded 16 participants with missing data for Lp(a) and 23 participants with missing data for MetS. Following these exclusions, 10, 336 participants were included in the analyses of MetS risk. The study protocol was approved by the Institutional Review Board of Ruijin...